Protective Effects of Sitagliptin on beta Cell Function in Patients With Adult-onset Latent Autoimmune Diabetes(LADA).

Trial Profile

Protective Effects of Sitagliptin on beta Cell Function in Patients With Adult-onset Latent Autoimmune Diabetes(LADA).

Completed
Phase of Trial: Phase I/II

Latest Information Update: 05 Jun 2015

At a glance

  • Drugs Sitagliptin (Primary) ; Insulin
  • Indications Latent autoimmune diabetes in adults
  • Focus Pharmacodynamics
  • Most Recent Events

    • 16 Jan 2014 Results published in the Journal of Clinical Endocrinology and Metabolism.
    • 30 Sep 2013 Status changed from recruiting to completed.
    • 25 Sep 2013 Results presented at the 49th Annual Meeting of the European Association for the Study of Diabetes.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top